Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$127.90
-1.2%
$132.59
$110.86
$141.23
$223.02B0.696.61 million shs4.21 million shs
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$184.63
-1.1%
$190.74
$163.33
$251.99
$53.01B0.252.43 million shs1.98 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$436.48
+0.2%
$456.15
$425.00
$616.00
$156.44B1.612.06 million shs875,394 shs
Stryker Corporation stock logo
SYK
Stryker
$368.53
-0.3%
$379.60
$329.16
$406.19
$141.09B0.941.41 million shs414,090 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.86%-3.79%-1.56%+7.12%+11.47%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-0.82%-3.66%+0.46%+3.29%-22.82%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
-0.18%-2.79%+0.37%-15.61%-8.96%
Stryker Corporation stock logo
SYK
Stryker
-0.18%-1.53%-2.09%-4.99%+2.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$127.90
-1.2%
$132.59
$110.86
$141.23
$223.02B0.696.61 million shs4.21 million shs
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$184.63
-1.1%
$190.74
$163.33
$251.99
$53.01B0.252.43 million shs1.98 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$436.48
+0.2%
$456.15
$425.00
$616.00
$156.44B1.612.06 million shs875,394 shs
Stryker Corporation stock logo
SYK
Stryker
$368.53
-0.3%
$379.60
$329.16
$406.19
$141.09B0.941.41 million shs414,090 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.86%-3.79%-1.56%+7.12%+11.47%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-0.82%-3.66%+0.46%+3.29%-22.82%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
-0.18%-2.79%+0.37%-15.61%-8.96%
Stryker Corporation stock logo
SYK
Stryker
-0.18%-1.53%-2.09%-4.99%+2.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.91
Moderate Buy$147.4415.28% Upside
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.25
Hold$205.4011.25% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.57
Moderate Buy$580.2932.95% Upside
Stryker Corporation stock logo
SYK
Stryker
2.71
Moderate Buy$431.7617.16% Upside

Current Analyst Ratings Breakdown

Latest BDX, ISRG, ABT, and SYK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$142.00 ➝ $146.00
10/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$147.00
10/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$141.00 ➝ $146.00
10/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$145.00 ➝ $150.00
10/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $149.00
10/16/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSector Perform$211.00
10/15/2025
Stryker Corporation stock logo
SYK
Stryker
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$415.00 ➝ $407.00
10/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$144.00 ➝ $142.00
10/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$145.00
10/15/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$600.00 ➝ $536.00
10/15/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$600.00 ➝ $525.00
(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.31$6.32 per share20.24$27.62 per share4.63
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.18B2.62$20.72 per share8.91$89.57 per share2.06
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$9.15B17.11$7.99 per share54.63$46.41 per share9.40
Stryker Corporation stock logo
SYK
Stryker
$23.82B5.92$15.02 per share24.53$54.13 per share6.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.9816.0622.322.5332.43%18.32%10.71%N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.5633.2611.801.477.51%16.23%7.46%11/6/2025 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$7.1760.8757.214.5828.51%14.56%12.93%10/21/2025 (Estimated)
Stryker Corporation stock logo
SYK
Stryker
$2.99B$7.5548.8824.852.6712.25%23.94%11.08%10/30/2025 (Estimated)

Latest BDX, ISRG, ABT, and SYK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q4 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.93N/AN/AN/A$5.91 billionN/A
10/30/2025Q3 2025
Stryker Corporation stock logo
SYK
Stryker
$3.14N/AN/AN/A$6.04 billionN/A
10/21/2025Q3 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.00N/AN/AN/A$2.41 billionN/A
10/15/2025Q3 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.30$1.30N/A$0.94$11.40 billion$11.37 billion
8/7/2025Q3 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.40$3.68+$0.28$1.99$5.50 billion$5.51 billion
7/31/2025Q2 2025
Stryker Corporation stock logo
SYK
Stryker
$3.07$3.13+$0.06$2.29$5.92 billion$6.02 billion
7/22/2025Q2 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.93$2.19+$0.26$1.81$2.35 billion$2.44 billion
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.85%N/A29.57%54 Years
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.25%N/A74.82%53 Years
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
Stryker Corporation stock logo
SYK
Stryker
$3.360.91%N/A44.50%32 Years

Latest BDX, ISRG, ABT, and SYK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/19/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.82%10/15/202510/15/202511/17/2025
8/7/2025
Stryker Corporation stock logo
SYK
Stryker
quarterly$0.840.91%9/30/20259/30/202510/31/2025
7/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.17%9/8/20259/8/20259/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.25
1.82
1.30
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.10
0.62
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
5.17
4.18
Stryker Corporation stock logo
SYK
Stryker
0.70
1.78
1.06

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
Stryker Corporation stock logo
SYK
Stryker
77.09%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
Stryker Corporation stock logo
SYK
Stryker
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
74,000286.63 million285.60 millionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
15,638358.48 million355.97 millionOptionable
Stryker Corporation stock logo
SYK
Stryker
53,000382.31 million359.75 millionOptionable

Recent News About These Companies

Nvest Financial LLC Raises Position in Stryker Corporation $SYK
Stryker Corporation $SYK Shares Sold by TD Asset Management Inc
6 Analysts Have This To Say About Stryker
BTIG Maintains Stryker (SYK) Buy Recommendation
Stryker price target raised to $408 from $407 at BTIG

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$127.90 -1.55 (-1.20%)
As of 01:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$184.63 -2.14 (-1.15%)
As of 01:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$436.48 +0.87 (+0.20%)
As of 01:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Stryker stock logo

Stryker NYSE:SYK

$368.52 -1.23 (-0.33%)
As of 01:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.